Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itepekimab - Regeneron Pharmaceuticals/Sanofi

Next Previous
Drug Profile

Itepekimab - Regeneron Pharmaceuticals/Sanofi

Alternative Names: REGN-3500; SAR-440340

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Bronchiectasis
  • No development reported Allergic asthma; Inflammation
  • Discontinued Asthma; Atopic dermatitis

Most Recent Events

  • 23 Feb 2024 Sanofi plans phase II trial for Bronchiectasis (SC, Injection) (NCT06280391; ACT18018)
  • 20 Feb 2024 Phase-II clinical trials in Bronchiectasis in United Kingdom (SC) (NCT06280391)
  • 11 Jan 2024 Phase-III clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced, In adults, In the elderly) in USA (SC) (NCT06208306)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top